Dr. Reddy's Laboratories Limited (RDY)
NYQ · Healthcare · Drug Manufacturers - Specialty & Generic
Closing price as of 2026-10-29 · Source: TEK2day Finance
Key Metrics
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Quarterly Financials (INR)
| Metric | 2025-12-31 | 2026-03-31 | 2026-06-30 | 2026-09-30 |
|---|---|---|---|---|
| Revenue | 87.3B | 75.2B | 80.7B | 86.7B |
| Gross Profit | 46.8B | 43.0B | 37.5B | 45.2B |
| Operating Income | 14.3B | 829.0M | 3.0B | 12.8B |
| Net Income | 12.1B | 2.2B | 4.4B | 9.2B |
| Diluted EPS | INR 14.52 | INR 2.65 | INR 5.32 | INR 11.10 |
Annual Financials (INR)
| Metric | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 245.9B | 279.2B | 325.5B | 335.9B |
| Gross Profit | 139.3B | 163.6B | 225.7B | 213.5B |
| Operating Income | 59.1B | 65.3B | 70.1B | 47.5B |
| Net Income | 45.1B | 55.7B | 56.6B | 42.0B |
| Diluted EPS | INR 54.17 | INR 66.92 | INR 67.79 | INR 50.35 |